(Q44589789)

4 December 2017

title

GPi pallidotomy for Parkinson's disease with drug-induced psychosis (English)

1 reference

4 December 2017

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S1353-8020(03)00072-5

11 March 2024

author name string

Kazumichi Yamada

1

1 reference

4 December 2017

Satoshi Goto

2

1 reference

4 December 2017

Yukitaka Ushio

3

1 reference

4 December 2017

language of work or name

1 reference

1 October 2003

1 reference

4 December 2017

number of pages

6

1 reference

full work available at URL

inferred from page(s)

https://api.elsevier.com/content/article/PII:S1353802003000725?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1353-8020(03)00072-5

https://api.elsevier.com/content/article/PII:S1353802003000725?httpAccept=text/plain

11 March 2024

1 reference

https://api.crossref.org/works/10.1016/S1353-8020(03)00072-5

Parkinsonism and Related Disorders

11 March 2024

published in

1 reference

4 December 2017

volume

10

1 reference

4 December 2017

issue

1

1 reference

4 December 2017

page(s)

35-40

1 reference

Sinemet and the treatment of Parkinsonism

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Chronic delusional hallucinatory psychosis in early-onset Parkinson's disease: drug-induced complication or sign of an idiopathic psychiatric illness?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Quetiapine as an Alternative to Clozapine in the Treatment of Dopamimetic Psychosis in Patients with Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Parkinson's disease: the treatment of drug-induced hallucinations and psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

1 reference

7 January 2021

Postoperative management of subthalamic nucleus stimulation for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Long-term efficacy of posteroventral pallidotomy in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Thalamic, subthalamic nucleus and internal pallidum stimulation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Subthalamic nucleus stimulation in patients with a prior pallidotomy.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Evaluation of surgery for Parkinson's disease: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The Task Force on Surgery for Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Bilateral stimulation of the subthalamic nucleus in patients with Parkinson disease: a study of efficacy and safety.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Core assessment program for intracerebral transplantations (CAPIT)

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Long-term follow up of subthalamic nucleus stimulation in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Temporal sequence of response to unilateral GPi pallidotomy of motor symptoms in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Posteroventral pallidotomy in a patient with parkinsonism caused by hypoxic encephalopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Bilateral pallidal stimulation for idiopathic segmental axial dystonia advanced from Meige syndrome refractory to bilateral thalamotomy

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Unilateral pallidotomy for Parkinson's disease: comparison of outcome in younger versus elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Efficacy of levodopa therapy on motor function after posteroventral pallidotomy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Neuropsychological and behavioral changes and weight gain after medial pallidotomy

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Neuropsychological consequences of posteroventral pallidotomy for the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

1 reference

7 January 2021

Stereotactic ventral pallidotomy for Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Effect of GPi pallidotomy on motor function in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Long term outcome of unilateral pallidotomy: follow up of 15 patients for 3 years

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Subthalamic nucleus stimulation in Parkinson's disease: clinical evaluation of 18 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900072-5

7 January 2021

Mental disorders in Parkinson's disease

3

1 reference

https://api.crossref.org/works/10.1016/S1353-8020(03)00072-5

11 March 2024

Identifiers

1 reference

4 December 2017

1 reference